2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1755

The Lymphotoxin/Megakaryoblastic Leukemia 1/Actin Axis As a Master Regulator of TLR Signaling in Lupus
Abstract Number: 2894

The Majority of Patients with Moderate to Severe Psoriatic Arthritis Had Existing Structural Damage, Predisposing Them to Further Progression, Which Was Markedly Inhibited By Adalimumab
Abstract Number: 2609

The Measurement of the Skin Autofluorescence As an Indicator of Disease Progression in Rheumatoid Arthritis Patients
Abstract Number: 1556

The Medication Information-Seeking Behaviors of Rheumatoid Arthritis Patients Who Are Prescribed a New DMARD
Abstract Number: 2560

The Mer Tyrosine Kinase Receptor Plays a Protective Role in Joint Inflammation By Mediating Efferocytosis
Abstract Number: 949

The Metabolic Syndrome, Its Elements and Knee Osteoarthritis: The Framingham Osteoarthritis (OA) Study
Abstract Number: 2817

The Microbiome of Reactive Arthritis in a Guatemalan Cohort
Abstract Number: 98

The Mitochondrial DNA (mtDNA) Haplogroups Influence the Risk of Incidence Knee OA. Replication Study Including Data from Check and OAI Cohorts
Abstract Number: 111

The Mitochondrial DNA (mtDNA) Haplogroups Influence the Risk of Radiographic OA Progression. a Meta-Analysis
Abstract Number: 112

The Molecular Genetic Analysis of the Autoinflammatory Syndromes in Russian Patients with Manifestation of Systemic Juvenile Idiopathic Arthritis
Abstract Number: 2629

The Most Frequent Fears and Beliefs of 226 Patients with Rheumatoid Arthritis or Spondyloarthritis, Using a Novel Questionnaire
Abstract Number: 2601

The Multi-Biomarker Disease Activity Score in a TNF Inhibitor Tapering Study in Rheumatoid Arthritis Patients: Predictive Value for Successful Tapering, Flaring and Radiographic Progression
Abstract Number: 618

The Multi-Biomarker Disease Activity Score in Methotrexate Incomplete Responders Predicts Clinical Responses to Non-Biological Versus Biological Therapy in Early RA
Abstract Number: 2542

The Multidimensional Assessment of Fatigue Scale: A 25-Year Review and Evaluation
Abstract Number: 907

The Natural History of an Inception Cohort of Patients with Inflammatory Polyarthritis Followed for 20 Years: Disease Activity, Disability and Surgery

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].